Today: 8 February 2026
Subscribe
Browse Category

Pharmaceuticals News 23 December 2025 - 27 December 2025

Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson shares closed at $207.63 Friday, down 0.07%, after the company halted a mid-stage trial of its eczema drug JNJ-5939 due to lack of efficacy. The drug was well-tolerated but failed to meet targets in interim analysis. JNJ’s market cap stands near $500 billion, with a 2.5% dividend yield. The stock traded at $207.86 after hours ahead of Monday’s market open.
27 December 2025
··
Merck (MRK) Stock Update: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Analyst Targets as Wall Street Heads Into New Year Week

Merck (MRK) Stock Update: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Analyst Targets as Wall Street Heads Into New Year Week

Merck shares closed at $106.78 Friday in New York, trading between $106.03 and $107.05 amid thin holiday liquidity. The company was named in a White House deal to cut U.S. drug prices through TrumpRx, offering discounts on drugs including JANUVIA. The S&P 500 ended near 6,929.94, with broader markets muted in post-Christmas trading.
27 December 2025
··
Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook

Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook

Eli Lilly shares closed Friday near $1,077.75, little changed after a narrow session. The Centers for Medicare & Medicaid Services this week announced a plan to expand GLP‑1 drug access, capping monthly costs at $50 for Medicare beneficiaries. A Trump-era pricing deal also sets lower reference prices for weight-loss drugs. Investors are watching policy shifts as key drivers for LLY’s valuation.
27 December 2025
··
Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026

Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026

Eli Lilly shares traded near $1,075 Friday afternoon, down 0.2% in thin post-Christmas trading as U.S. indexes hovered close to record highs. The stock moved between $1,068 and $1,082 amid muted volume. The NYSE and Nasdaq remained open for a regular session. Investors continue to watch Lilly’s pricing moves and its lead in obesity and diabetes treatments.
26 December 2025
··
GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK’s U.S. ADR closed at $48.96 after the FDA approved its twice-yearly asthma drug Exdensur, but withheld approval for a related use. The company also reached a U.S. drug-pricing deal affecting its respiratory products and reported progress on vaccine expansion in Europe. London trading paused for holidays. Shingrix faces new competition.
26 December 2025
···
Merck (MRK) Stock: Key News, Analyst Targets, and Catalysts to Know Before the Market Opens Dec. 26, 2025

Merck (MRK) Stock: Key News, Analyst Targets, and Catalysts to Know Before the Market Opens Dec. 26, 2025

U.S. stock markets were closed Dec. 25 for Christmas and will reopen Dec. 26 after an early close Dec. 24. Merck shares last traded near $106.45. The White House named Merck in new drug-pricing agreements announced Dec. 19, with Merck confirming plans for steep discounts on key diabetes drugs. Merck’s next earnings call is scheduled for Feb. 3, 2026.
26 December 2025
··
Eli Lilly (LLY) Stock: Key News, Catalysts, Forecasts and Risks to Watch Before the Dec. 26, 2025 Market Open

Eli Lilly (LLY) Stock: Key News, Catalysts, Forecasts and Risks to Watch Before the Dec. 26, 2025 Market Open

Eli Lilly and Company (NYSE: LLY) heads into the Friday, Dec. 26, 2025 U.S. market open with investors balancing two powerful forces: policy-driven price pressure on GLP‑1 drugs and pipeline-driven growth potential that keeps Lilly at the center of the obesity and diabetes mega-trend. Because Christmas Day (Dec. 25) is a market holiday and Christmas Eve (Dec. 24) was an early close, the next “real” price discovery for LLY happens when trading resumes Friday morning—often with thinner holiday-week liquidity that can exaggerate moves. New York Stock Exchange Below is what matters most—the latest headlines, what Wall Street is forecasting, and
26 December 2025
··
Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story

Merck shares closed at $106.45 on Dec. 24, capping a six-day rally driven by a BMO Capital Markets upgrade to Outperform and a new $130 price target. Analysts cited confidence in Merck’s pipeline as it prepares for Keytruda’s 2028 loss of exclusivity. Recent gains also follow positive oncology data and a European regulatory milestone for Winrevair. U.S. markets were closed Dec. 25 for Christmas.
25 December 2025
·
Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

The U.S. FDA approved Novo Nordisk’s Wegovy pill, the first oral GLP-1 drug for chronic weight management, on Dec. 22. Novo Nordisk ADRs closed at $52.56 on Dec. 24, up 1.8% after the news. The company plans a U.S. launch in early January 2026. Trial data showed a mean weight loss of 16.6% for patients adhering to the regimen.
25 December 2025
·
Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum

Merck shares hit a 52-week high near $106.50 on December 24 after a six-day, 8.3% rally. The surge followed a BMO Capital Markets upgrade to “Outperform” with a $130 target and positive late-stage trial results for Keytruda combinations in bladder cancer. European regulators advanced WINREVAIR for pulmonary hypertension. U.S. markets were closed December 25.
25 December 2025
··
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer shares traded near $25 on Dec. 24, 2025, valuing the company at about $142 billion amid thin holiday trading. The company’s 2026 guidance, released Dec. 16, projects revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, with growth not expected to rebound until later in the decade. Investors remain focused on drug pricing risks, pipeline progress, and looming patent expirations.
24 December 2025
···
Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

Zai Lab Limited (ZLAB) Stock Surges After China Approves COBENFY for Schizophrenia: News, Forecasts, and Analyst Outlook on Dec. 24, 2025

China’s NMPA approved Zai Lab’s COBENFY for adult schizophrenia on Dec. 23, triggering a surge in Zai Lab shares. The U.S. ADR traded around $18.54 intraday, while Hong Kong shares closed at HK$14.48, up 6.24%. COBENFY is the first M1/M4 muscarinic receptor therapy for schizophrenia approved in China. Zai Lab holds exclusive commercialization rights in Greater China.
24 December 2025
···
Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck Stock Forecast and News Roundup for December 24, 2025: MRK Hits a New 52-Week High as Wall Street Reprices 2026 Catalysts

Merck shares hit a 12-month high near $106 on December 24, 2025, capping a 30% rally over three months. The surge follows a Trump administration deal requiring Merck to cut prices on drugs like Januvia for Medicaid and direct-to-consumer sales. Analysts cite optimism about Merck’s growth beyond Keytruda’s patent expiration and progress on new drugs.
24 December 2025
··
Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson traded near $207 per share in thin holiday trading Wednesday, keeping its market value around $500 billion. A Baltimore jury ordered the company to pay over $1.5 billion in a talc cancer case, the largest such verdict to date. J&J said it will appeal. U.S. markets close early at 1 p.m. ET for Christmas Eve.
24 December 2025
···
Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition

Recursion Pharmaceuticals shares traded near $4.37 on December 24, 2025, after J.P. Morgan upgraded the stock and Cathie Wood’s ARK funds increased their position. Trading volume was in the low millions during the early-close Christmas Eve session. The moves follow positive clinical data from REC-4881’s Phase 1b/2 trial in FAP. RXRX’s market cap stands at roughly $2.12 billion.
24 December 2025
·
Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly shares rose 0.47% to $1,076.67 in light Christmas Eve trading, with volume just over 200,000 shares by late morning. Investors focused on new GLP-1 headlines, including regulatory updates and global expansion, as well as a Reuters report showing Lilly’s Mounjaro outpacing Novo’s Wegovy in India since March. Indian generics are expected to intensify competition as patent expiries approach.
24 December 2025
···
Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

U.S. regulators have approved Novo Nordisk’s oral Wegovy pill for weight management and cardiovascular risk reduction, sending NVO shares higher earlier this week. Analysts are watching pricing and insurance coverage in the U.S., as well as competition in India ahead of 2026 generic launches. The pill is expected to reach U.S. patients in January. NVO stock traded in the low-$50s on Dec. 24.
24 December 2025
···
Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva shares closed at $31.54 on Dec. 23, up 28% since Nov. 5, after S&P Global Ratings upgraded the company’s credit to ‘BB+’ on improved deleveraging. The stock traded near $31.93 pre-market Dec. 24. Analysts, including Piper Sandler, have raised price targets as Teva’s pipeline and biosimilars schedule gains clarity. Investors remain alert to pricing and patent risks.
24 December 2025
··
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals shares fell to $0.32 on December 24, 2025, after the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine before a New Drug Application. The company said the new trial, RECOVER-2, could cost $60 million and delay potential approval to late 2028. Reviva plans to start the trial in the first half of 2026, pending financing.
24 December 2025
···
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics shares traded near $67.50 on Dec. 23, 2025, following strong Phase 2 data for its oral obesity drug aleniglipron, which showed up to 15.3% placebo-adjusted weight loss at 36 weeks. The company also closed a $747.5 million public offering after the trial results.
23 December 2025
····
1 … 18 19 20 21 22 … 34

Stock Market Today

National Grid share price on a six-session run: what could move NG.L when London reopens

National Grid share price on a six-session run: what could move NG.L when London reopens

8 February 2026
National Grid closed Friday at 1,285 pence, up 0.23%, marking its sixth straight gain and trading near a 52-week high. Investors focused on Bank of England survey results showing expectations for Bank Rate to fall to 3.0% by March 2027. UK GDP, trade, and industrial output data are due Feb. 12. 6.51 million National Grid shares changed hands in the session.
Idox share price stuck below 71.5p bid as Long Path says backing nears control

Idox share price stuck below 71.5p bid as Long Path says backing nears control

8 February 2026
Long Path Partners said it has aggregate support for about 49.26% of Idox shares for its 71.5p-per-share cash offer. Idox shares closed Friday at 71.0p, about 0.7% below the offer price. Valid acceptances stood at 19.12% as of Feb. 5, with the offer open until March 16. The deal requires more than 50% of voting rights to go unconditional.
Go toTop